阿替韋單抗/馬菲替馬單抗/奧德西維馬單抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "阿替韋單抗/馬菲替馬單抗/奧德西維馬單抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

20web.archive.org

1^st place

5fda.gov

447^th place

581^st place

5nih.gov

4^th place

5^th place

2doi.org

2^nd place

23^rd place

2who.int

195^th place

179^th place

2regeneron.com

low place

1medscape.com

719^th place

889^th place

1handle.net

102^nd place

492^nd place

1futurity.org

low place

1harvard.edu

18^th place

57^th place

1worldcat.org

5^th place

12^th place

1arstechnica.com

388^th place

546^th place

1nytimes.com

7^th place

31^st place

1theafricareport.com

8,967^th place

low place

1wired.com

193^rd place

421^st place

1nature.com

234^th place

227^th place

arstechnica.com (Global: 388^th place; Chinese: 546^th place)

Mole B. Two Ebola drugs boost survival rates, according to early trial data. Ars Technica. 2019-08-13 [2019-08-17]. （原始内容存档于2021-02-25）.

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Check Hayden, Erika. Experimental drugs poised for use in Ebola outbreak. Nature. May 2018, 557 (7706): 475–476. Bibcode:2018Natur.557..475C. ISSN 0028-0836. PMID 29789732. doi:10.1038/d41586-018-05205-x .
Saxena, D.; Kaul, G. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc). August 2021, 57 (8): 483–490 [2024-11-22]. doi:10.1358/dot.2021.57.8.3280599. （原始内容存档于2024-12-07）.

fda.gov (Global: 447^th place; Chinese: 581^st place)

fda.gov

FDA Approves First Treatment for Ebola Virus. U.S. Food and Drug Administration (FDA) (新闻稿). 14 October 2020 [14 October 2020]. （原始内容存档于2020-10-15）. 本文含有此來源中屬於公有领域的内容。
Drug Trials Snapshots: Inmazeb. U.S. Food and Drug Administration. 2020-10-14 [2020-10-23]. （原始内容存档于2020-11-01）. 本文含有此來源中屬於公有领域的内容。
New Drug Therapy Approvals 2020. U.S. Food and Drug Administration (FDA). 2020-12-31 [2021-01-17]. （原始内容存档于2021-01-18）.

accessdata.fda.gov

Inmazeb: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-10-15]. （原始内容存档于2020-10-21）.
Drug Approval Package: Inmazeb. U.S. Food and Drug Administration. 2020-11-12 [2020-12-23]. （原始内容存档于2020-12-09）.

futurity.org (Global: low place; Chinese: low place)

Ebola Treatment Massively Cuts Death Rate, But It's No Cure. Futurity. 2019-08-16 [2019-11-07]. （原始内容存档于2019-11-07）.

handle.net (Global: 102^nd place; Chinese: 492^nd place)

hdl.handle.net

World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.

harvard.edu (Global: 18^th place; Chinese: 57^th place)

ui.adsabs.harvard.edu

Check Hayden, Erika. Experimental drugs poised for use in Ebola outbreak. Nature. May 2018, 557 (7706): 475–476. Bibcode:2018Natur.557..475C. ISSN 0028-0836. PMID 29789732. doi:10.1038/d41586-018-05205-x .

medscape.com (Global: 719^th place; Chinese: 889^th place)

reference.medscape.com

atoltivimab/maftivimab/odesivimab (Rx). Medscape. [2024-11-21]. （原始内容存档于2024-12-08）.

nature.com (Global: 234^th place; Chinese: 227^th place)

Two Ebola drugs show promise amid ongoing outbreak. Nature. [2019-11-06]. （原始内容存档于2019-11-29）.

nih.gov (Global: 4^th place; Chinese: 5^th place)

dailymed.nlm.nih.gov

Inmazeb- atoltivimab, maftivimab, and odesivimab-ebgn injection, solution. DailyMed. [17 January 2021]. （原始内容存档于2021-01-22）.

ncbi.nlm.nih.gov

Check Hayden, Erika. Experimental drugs poised for use in Ebola outbreak. Nature. May 2018, 557 (7706): 475–476. Bibcode:2018Natur.557..475C. ISSN 0028-0836. PMID 29789732. doi:10.1038/d41586-018-05205-x .

nytimes.com (Global: 7^th place; Chinese: 31^st place)

McNeil DG. A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo. The New York Times. 2019-08-12 [2019-08-13]. （原始内容存档于2019-08-12）.

regeneron.com (Global: low place; Chinese: low place)

newsroom.regeneron.com

Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus). Regeneron Pharmaceuticals Inc. (新闻稿). 2020-10-14 [2020-10-14]. （原始内容存档于2020-10-15）.

regeneron.com

Stahl, Niel. Making a Drug You Hope No One Will Ever Need Harnessing the Power of Technology for Good. [6 November 2019]. （原始内容存档于2019-09-18）.

theafricareport.com (Global: 8,967^th place; Chinese: low place)

Kingsley-Hall A. Congo's experimental mAb114 Ebola treatment appears successful: authorities | Central Africa. www.theafricareport.com. [2018-10-15]. （原始内容存档于2018-12-23）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Inmazeb- atoltivimab, maftivimab, and odesivimab-ebgn injection, solution. DailyMed. [17 January 2021]. （原始内容存档于2021-01-22）.
FDA Approves First Treatment for Ebola Virus. U.S. Food and Drug Administration (FDA) (新闻稿). 14 October 2020 [14 October 2020]. （原始内容存档于2020-10-15）. 本文含有此來源中屬於公有领域的内容。
atoltivimab/maftivimab/odesivimab (Rx). Medscape. [2024-11-21]. （原始内容存档于2024-12-08）.
Drug Trials Snapshots: Inmazeb. U.S. Food and Drug Administration. 2020-10-14 [2020-10-23]. （原始内容存档于2020-11-01）. 本文含有此來源中屬於公有领域的内容。
Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus). Regeneron Pharmaceuticals Inc. (新闻稿). 2020-10-14 [2020-10-14]. （原始内容存档于2020-10-15）.
Inmazeb: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-10-15]. （原始内容存档于2020-10-21）.
Drug Approval Package: Inmazeb. U.S. Food and Drug Administration. 2020-11-12 [2020-12-23]. （原始内容存档于2020-12-09）.
New Drug Therapy Approvals 2020. U.S. Food and Drug Administration (FDA). 2020-12-31 [2021-01-17]. （原始内容存档于2021-01-18）.
Ebola Treatment Massively Cuts Death Rate, But It's No Cure. Futurity. 2019-08-16 [2019-11-07]. （原始内容存档于2019-11-07）.
Stahl, Niel. Making a Drug You Hope No One Will Ever Need Harnessing the Power of Technology for Good. [6 November 2019]. （原始内容存档于2019-09-18）.
WHO: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions for Ebola virus Disease (PDF). who.int. World Health Organization. 2018-05-17 [2021-11-02]. （原始内容存档 (PDF)于2020-11-09）.
NIH VideoCast - CC Grand Rounds: Response to an Outbreak: Ebola Virus Monoclonal Antibody (mAb114) Rapid Clinical Development. videocast.nih.gov. 2019-03-13 [2019-08-09]. （原始内容存档于2021-08-29）.
Mole B. Two Ebola drugs boost survival rates, according to early trial data. Ars Technica. 2019-08-13 [2019-08-17]. （原始内容存档于2021-02-25）.
Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates. National Institutes of Health (NIH). 2019-08-12 [2019-08-17]. （原始内容存档于2021-04-11）.
McNeil DG. A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo. The New York Times. 2019-08-12 [2019-08-13]. （原始内容存档于2019-08-12）.
Kingsley-Hall A. Congo's experimental mAb114 Ebola treatment appears successful: authorities | Central Africa. www.theafricareport.com. [2018-10-15]. （原始内容存档于2018-12-23）.
Molteni M. Ebola is Now Curable. Here's How The New Treatments Work. Wired. 2019-08-12 [2019-08-13]. （原始内容存档于2019-08-13）.
Two Ebola drugs show promise amid ongoing outbreak. Nature. [2019-11-06]. （原始内容存档于2019-11-29）.
Ebola virus disease – Democratic Republic of the Congo. WHO. 2020-01-23 [2020-01-28]. （原始内容存档于2020-05-05）.
Saxena, D.; Kaul, G. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc). August 2021, 57 (8): 483–490 [2024-11-22]. doi:10.1358/dot.2021.57.8.3280599. （原始内容存档于2024-12-07）.

who.int (Global: 195^th place; Chinese: 179^th place)

WHO: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions for Ebola virus Disease (PDF). who.int. World Health Organization. 2018-05-17 [2021-11-02]. （原始内容存档 (PDF)于2020-11-09）.
Ebola virus disease – Democratic Republic of the Congo. WHO. 2020-01-23 [2020-01-28]. （原始内容存档于2020-05-05）.

wired.com (Global: 193^rd place; Chinese: 421^st place)

Molteni M. Ebola is Now Curable. Here's How The New Treatments Work. Wired. 2019-08-12 [2019-08-13]. （原始内容存档于2019-08-13）.

worldcat.org (Global: 5^th place; Chinese: 12^th place)

Check Hayden, Erika. Experimental drugs poised for use in Ebola outbreak. Nature. May 2018, 557 (7706): 475–476. Bibcode:2018Natur.557..475C. ISSN 0028-0836. PMID 29789732. doi:10.1038/d41586-018-05205-x .

阿替韋單抗/馬菲替馬單抗/奧德西維馬單抗 (Chinese Wikipedia)

arstechnica.com (Global: 388th place; Chinese: 546th place)

doi.org (Global: 2nd place; Chinese: 23rd place)

fda.gov (Global: 447th place; Chinese: 581st place)

fda.gov

accessdata.fda.gov

futurity.org (Global: low place; Chinese: low place)

handle.net (Global: 102nd place; Chinese: 492nd place)

hdl.handle.net

harvard.edu (Global: 18th place; Chinese: 57th place)

ui.adsabs.harvard.edu

medscape.com (Global: 719th place; Chinese: 889th place)

reference.medscape.com

nature.com (Global: 234th place; Chinese: 227th place)

nih.gov (Global: 4th place; Chinese: 5th place)

dailymed.nlm.nih.gov

ncbi.nlm.nih.gov

videocast.nih.gov

nih.gov

pubmed.ncbi.nlm.nih.gov

nytimes.com (Global: 7th place; Chinese: 31st place)

regeneron.com (Global: low place; Chinese: low place)

newsroom.regeneron.com

regeneron.com

theafricareport.com (Global: 8,967th place; Chinese: low place)

web.archive.org (Global: 1st place; Chinese: 1st place)

who.int (Global: 195th place; Chinese: 179th place)

wired.com (Global: 193rd place; Chinese: 421st place)

worldcat.org (Global: 5th place; Chinese: 12th place)

arstechnica.com (Global: 388^th place; Chinese: 546^th place)

doi.org (Global: 2^nd place; Chinese: 23^rd place)

fda.gov (Global: 447^th place; Chinese: 581^st place)

handle.net (Global: 102^nd place; Chinese: 492^nd place)

harvard.edu (Global: 18^th place; Chinese: 57^th place)

medscape.com (Global: 719^th place; Chinese: 889^th place)

nature.com (Global: 234^th place; Chinese: 227^th place)

nih.gov (Global: 4^th place; Chinese: 5^th place)

nytimes.com (Global: 7^th place; Chinese: 31^st place)

theafricareport.com (Global: 8,967^th place; Chinese: low place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)

who.int (Global: 195^th place; Chinese: 179^th place)

wired.com (Global: 193^rd place; Chinese: 421^st place)

worldcat.org (Global: 5^th place; Chinese: 12^th place)